Treatment of Prostate Cancer With Firmagon®

Effectiveness and Safety as Well as Adherence of the S3 Guidelines for the Treatment of Prostate Cancer in the Treatment of Patients of Patients With Firmagon®

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01710098

Enrollment

100

Registered

2012-10-18

Start date

2012-06-30

Completion date

2015-09-24

Last updated

2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

testosterone, S3-Adherence, Quality of Life

Brief summary

How are testosterone levels of patients with prostate cancer under treatment with Firmagon® changing. Former studies showed a quick fall of testosterone levels after start of therapy with Firmagon® and a quick recovery when therapy is stopped. The investigators want to prove this in a normal outpatient urologist setting. Furthermore data is collected to prove the adherence to the German S3-Guideline for the treatment of prostate cancer.

Interventions

DRUGDegarelix

subcutaneous injection

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to 95 Years

Healthy volunteers

Inclusion criteria

* advanced hormone-dependent prostate cancer with no other previous hormone therapy for whom - irrespectively of this NIS -the use of Firmagon® is intended

Exclusion criteria

* contraindication for Degarelix

Design outcomes

Primary

Measure	Time frame
PSA-/Testosterone Level	12 months

Secondary

Measure	Time frame	Description
S3 Guideline	12 months	Percentage of patients who have been treated in accordance with the grade A recommendations of the S3 guideline for treatment of prostate cancer
Anxiety	12 Months	Anxiety score

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026